FrancophonIA/ELRC3.0 huggingface dataset:
English: No negative influence on gestation, foaling and offspring of mares was observed after vaccination at different times during pregnancy.
Estonian: Tiinuse eri etappides toimunud vaktsineerimise järel ei täheldatud negatiivset mõju tiinusele, poegimisele ega märade järglastele.
English: The studies showed that Equilis Te is an effective vaccine against tetanus to prevent mortality in horses from 6 months of age.
Estonian: Uuringud näitasid Equilis Te efektiivust vaktsiinina teetanuse vastu, mis ennetab suremust vähemalt 6 kuu vanustel hobustel.
English: When the product is given to horses, it helps the animals' immune system to react quicker when the animal is naturally exposed to the Clostridium tetani bacterium.
Estonian: Kui loom puutub Clostridium tetani bakteriga kokku loomulikul teel hiljem uuesti, aitab hobustele manustatud ravim looma immuunsüsteemil kiiremini reageerida.
English: Pain at the injection site can occur occasionally.
Estonian: Aeg-ajalt esineb ka süstepiirkonna valulikkust.
English: Other information about Equilis Te:
Estonian: Muu teave Equilis Te kohta
English: The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Equilis Te exceeded the risks for the immunisation of horses from six months of age against tetanus to prevent mortality.
Estonian: Veterinaarravimite komitee otsustas, et Equilis Te kasulikkus selle kasutamisel vähemalt 6 kuu vanuste hobuste vaktsineerimiseks teetanuse vastu suremuse ennetamiseks, on suurem kui sellega kaasnevad riskid.
English: How has Equilis Te been studied?
Estonian: Kuidas Equilis Ted uuriti?
English: What is Equilis Te used for?
Estonian: Milleks Equilis Ted kasutatakse?
English: 09 December 2015 EMA/680058/2015
Estonian: 9. detsember 2015. a EMA/680058/2015
English: If the symptoms persist for more than 2 weeks, a doctor or a qualified health care practitioner should be consulted.
Estonian: Kui sümptomid püsivad kauem kui 2 nädalat, tuleb pöörduda arsti või pädeva tervishoiutöötaja poole.
English: Fresh bilberry fruit medicines should only be used in adults and should not be taken for longer than 4 weeks.
Estonian: Värskeid mustikaid sisaldavaid ravimeid tohivad kasutada üksnes täiskasvanud ja neid ei tohi võtta kauem kui 4 nädalat.
English: In its assessment, the HMPC also considered clinical studies on disorders of the circulatory system which were performed 30 - 40 years ago.
Estonian: Taimsete ravimite komitee uuris hinnangu andmisel ka kliinilisi uuringuid vereringesüsteemi häirete kohta, mis olid läbi viidud 30...40 aastat tagasi.
English: Fresh bilberry fruit EMA/680058/2015
Estonian: Värsked mustikad EMA/680058/2015
English: Although possible beneficial effects were observed, there were limitations in the way the studies were conducted and, therefore, the HMPC conclusions on the use of fresh bilberry fruit medicines are based on their long-standing use.
Estonian: Kuigi täheldati võimalikku mõju, ilmnesid nende uuringute läbiviimisel puudused ja seetõttu põhineb taimsete ravimite komitee järeldus värskeid mustikaid sisaldavate ravimite kasutamise kohta nende pikaajalisel kasutamisel.
English: Further information on the HMPC assessment of fresh bilberry fruit medicines, including details of the Committee's conclusions, can be found under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Estonian: Lisateave värskeid mustikaid sisaldavate ravimite hindamise kohta, sh komitee kokkuvõtte üksikasjalik kirjeldus, on Euroopa Ravimiameti veebilehe jaotises „All documents”: ema.europa.eu/Find medicine/Herbal medicines for human use.
English: Further information on the risks associated with fresh bilberry fruit medicines, including the appropriate precautions for their safe use, can be found in the monograph under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Estonian: Lisateave nende värskeid mustikaid sisaldavate ravimitega kaasnevate riskide, sh selle ohutu kasutamise ettevaatusabinõude kohta, on taimse aine monograafias Euroopa Ravimiameti veebilehe jaotises „All documents”: ema.europa.eu/Find medicine/Herbal medicines for human use.
English: Detailed instructions on how to take fresh bilberry fruit medicines and who can use them can be found in the package leaflet that comes with the medicine.
Estonian: Üksikasjalik teave, kuidas võtta värskeid mustikaid sisaldavaid ravimeid ja kes neid tohib kasutada, on ravimi pakendi infolehel.
English: Any applications for the licensing of medicines containing fresh bilberry fruit have to be submitted to the national authorities responsible for medicinal products, which will assess the application for the herbal medicine and take into account the scientific conclusions of the HMPC.
Estonian: Värskeid mustikaid sisaldavate ravimite müügiloa taotlus tuleb esitada riiklikule ravimiametile, mis hindab taimsete ravimite müügiloa taotlust, võttes arvesse taimsete ravimite komitee teaduslikke järeldusi.
English: Other information about fresh bilberry fruit medicines
Estonian: Muu teave värskeid mustikaid sisaldavate ravimite kohta
English: Information on the use and licensing of fresh bilberry fruit medicines in EU Member States should be obtained from the relevant national authorities.
Estonian: ELi liikmesriikides saab värskeid mustikaid sisaldavate ravimite kasutamise ja müügilubade teavet asjakohastelt riiklikelt ravimiametitelt.
English: This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of fresh bilberry fruit.
Estonian: See on taimsete ravimite komitee teaduslike järelduste kokkuvõte, mis käsitleb värskete mustikate meditsiinilisi kasutusviise.
English: The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing fresh bilberry fruit.
Estonian: ELi liikmesriigid võtavad taimsete ravimite komitee järeldusi arvesse, kui nad hindavad värskeid mustikaid sisaldavate taimsete ravimite müügilubade taotlusi.
English: The HMPC conclusions on the use of fresh bilberry fruit medicines for relief of discomfort and heaviness of legs related to minor blood circulatory problems and for relief of symptoms of bleeding into the skin from tiny blood vessels are based on their ‘traditional use'.
Estonian: Taimsete ravimite komitee järeldused värskeid mustikaid sisaldavate ravimite kohta väikeste veresoonte vereringeprobleemidest tingitud ebamugavus- ja raskustunde leevendamiseks jalgades ning väikestest veresoontest lähtuvate nahaverejooksu sümptomite leevendamiseks põhinevad nende traditsioonilisel kasutamisel.
English: What is fresh bilberry fruit?
Estonian: Mis on värsked mustikad?
English: Results from laboratory studies indicate that bilberries are rich in anthocyanins, which are thought to improve blood circulation by relaxing and dilating (widening) blood vessels and protecting blood vessels from damage.
Estonian: Laborikatsete tulemused näitavad, et mustikates on palju antotsüaniine, mis parandavad vereringet lõõgastades ja laiendades veresooni ning kaitstes veresooni kahjustuste eest.
English: What evidence supports the use of fresh bilberry fruit medicines?
Estonian: Mis tõendid toetavad värskeid mustikaid sisaldavate ravimite kasutamist?
English: How are fresh bilberry fruit medicines approved in the EU?
Estonian: Kuidas antakse Euroopa Liidus värskeid mustikaid sisaldavate ravimite müügiluba?
English: Fresh bilberry fruit
Estonian: Värsked mustikad
English: Herbal medicines containing fresh bilberry fruit preparations are usually available in solid forms to be taken by mouth.
Estonian: Värskeid mustikaid sisaldavaid taimseid ravimeid turustatakse tavaliselt suukaudsete tahkete ravimvormidena.
English: The HMPC concluded that, on the basis of its long-standing use, fresh bilberry fruit medicines can be used to relieve discomfort and heaviness of legs related to minor blood circulatory problems and to relieve symptoms of bleeding into the skin from tiny blood vessels.
Estonian: Taimsete ravimite komitee järeldas, et lähtudes pikaajalisest kasutusest tohib värskete mustikate valmistisi kasutada väikeste veresoonte vereringeprobleemidest tingitud ebamugavus- ja raskustunde leevendamiseks jalgades ning väikestest veresoontest lähtuvate nahaverejooksu sümptomite leevendamiseks.
English: This summary is not intended to provide practical advice on how to use medicines containing fresh bilberry fruit.
Estonian: Kokkuvõttes ei anta värskeid mustikaid sisaldavate ravimite kasutamise praktilisi nõuandeid.
English: For more information about treatment with fresh bilberry fruit medicines, read the package leaflet that comes with the medicine or contact your doctor or pharmacist.
Estonian: Kui vajate värskeid mustikaid sisaldavate ravimitega toimuva ravi kohta lisateavet, lugege palun ravimi pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: What are the risks associated with fresh bilberry fruit medicines?
Estonian: Mis riskid värskeid mustikaid sisaldavate ravimitega kaasnevad?
English: The anthocyanins are also thought to repair tiny blood vessels after damage to the local circulation.
Estonian: Arvatakse, et antotsüaniinid parandavad väikeseid veresooni lokaalse vereringe kahjustuse järel.
English: For practical information about using fresh bilberry fruit medicines, patients should read the package leaflet that comes with the medicine or contact their doctor or pharmacist.
Estonian: Kui vajate värskeid mustikaid sisaldavate ravimite kasutamise kohta praktilisi nõuandeid, lugege ravimi pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Fresh bilberry fruit is the common name for the fresh fruit of the plant Vaccinium myrtillus L. Fresh bilberry fruit preparations are obtained using a technique to extract compounds from fresh plant material by dissolving them in a solvent (such as methanol), which is then evaporated to obtain a dry extract.
Estonian: Värskete mustikate valmistisi saadakse värskete taimeosade asetamisel lahustisse (nt metanooli), mis seejärel aurustatakse, et järele jääks kuivekstrakt.
English: What are the HMPC conclusions on its medicinal uses?
Estonian: Mis on taimsete ravimite komitee järeldused värskete mustikate meditsiiniliste kasutusalade kohta?
English: The European Commission granted a marketing authorisation valid throughout the European Union for Jentadueto on 20 July 2012.
Estonian: Euroopa Komisjon andis Jentadueto müügiloa, mis kehtib kogu Euroopa Liidus, 20. juulil 2012.
English: This summary was last updated in 05-2016
Estonian: Kokkuvõtte viimane uuendus: 05-2016.
English: The full EPAR for Jentadueto can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Jentadueto kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Other information about Jentadueto
Estonian: Muu teave Jentadueto kohta
English: What extra measures are being taken to ensure the safe and effective use of Jentadueto?
Estonian: Mis meetmed võetakse, et tagada Jentadueto ohutu ja efektiivne kasutamine?
English: Jentadueto is taken twice a day.
Estonian: Jentaduetot võetakse kaks korda ööpäevas.
English: A risk management plan has been developed to ensure that Jentadueto is used as safely and effectively as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Jentadueto võimalikult ohutu kasutamine.
English: Jentadueto must not be used in patients with:
Estonian: Jentaduetot ei tohi kasutada patsiendid, kellel on
English: The CHMP noted that fixed dose combinations may increase the likelihood of patients taking their medicine correctly.
Estonian: Komitee märkis, et fikseeritud annuse kombinatsioonid suurendavad tõenäosust, et patsiendid võtavad ravimeid õigesti.
English: • diabetic ketoacidosis or diabetic pre-coma (dangerous complications of diabetes);
Estonian: • diabeetiline ketoatsidoos või diabeetiline prekooma (diabeedi ohtlikud tüsistused);
English: This is a summary of the European public assessment report (EPAR) for Jentadueto.
Estonian: See on ravimi Jentadueto Euroopa avaliku hindamisaruande kokkuvõte.
English: With regard to side effects, the Committee considered that in general the risks seen were only slightly greater than those seen with placebo.
Estonian: Kõrvalnähtude kohta märkis inimravimite komitee, et tuvastatud riskid on üldiselt ainult veidi suuremad kui platseebo korral.
English: It is available as tablets (2.5 mg/850 mg and 2.5 mg/1,000 mg).
Estonian: Seda turustatakse tablettidena (2,5 mg / 850 mg ja 2,5 mg / 1000 mg).
English: Therefore the CHMP decided that Jentadueto's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Seetõttu otsustas inimravimite komitee, et Jentadueto kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: Linagliptin has been authorised in the European Union (EU) as Trajenta since 2011.
Estonian: Linagliptiin on ravimina Trajenta Euroopa Liidus heaks kiidetud alates 2011. aastast.
English: • in patients who are already taking a combination of linagliptin and metformin as separate tablets;
Estonian: • patsientidel, kes juba võtavad linagliptiini ja metformiini eraldi tablettidena;
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Jentadueto, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Jentadueto omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: For more information about treatment with Jentadueto, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Jentaduetoga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: • a condition that could lead to reduced supply of oxygen to body tissues (such as in patients who are being treated for worsening heart failure, have recently had a heart attack, have difficulty breathing or a steep fall in blood pressure);
Estonian: • seisund, mis võib vähendada kudede hapnikuvarustust (nt süveneva südamepuudulikkuse, hiljutise südameinfarkti, hingamisraskuste või vererõhu suure langusega patsientidel);
English: The study compared the effects of adding linagliptin to metformin in these ways, since metformin needs to be taken at least twice per day.
Estonian: Uuringus võrreldi metformiinile lisatud linagliptiini toimet, sest metformiini peab võtma vähemalt kaks korda ööpäevas.
English: Jentadueto should be taken with food to reduce stomach problems caused by metformin.
Estonian: Jentaduetot peab võtma koos toiduga, et vähendada metformiinist tingitud maoprobleeme.
English: What is Jentadueto?
Estonian: Mis on Jentadueto?
English: In all studies, the main measure of effectiveness was the change in blood levels of a substance called glycosylated haemoglobin (HbA1c) after 24 weeks of treatment.
Estonian: Kõikides uuringutes oli efektiivsuse põhinäitaja glükoseerunud hemoglobiini (HbA1c) sisalduse muutus veres pärast 24-nädalast ravi.
English: The studies looked at the effectiveness of linagliptin used on its own (503 patients), in combination with metformin (701 patients), with metformin plus a sulphonylurea (1,058 patients) or with another diabetes medicine pioglitazone (389 patients).
Estonian: Uuringutes jälgiti linagliptiini efektiivsust kasutamisel üksikravimina (503 patsienti), koos metformiiniga (701 patsienti), koos metformiini ja sulfonüüluurearavimiga (1058 patsienti) või koos teise diabeediravimi pioglitasooniga (389 patsienti).
English: Jentadueto is a medicine that contains the active substances linagliptin and metformin hydrochloride.
Estonian: Jentadueto on ravim, mis sisaldab toimeainetena linagliptiini ja metformiinvesinikkloriidi.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Jentadueto.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Jentadueto linagliptin / metformin hydrochloride
Estonian: Jentadueto linagliptiin/metformiinvesinikkloriid
English: By prolonging the action of incretin hormones in the blood, linagliptin stimulates the pancreas to produce more insulin when blood glucose levels are high.
Estonian: Pikendades veres sisalduvate inkretiinhormoonide toimet, stimuleerib linagliptiin kõhunääret tekitama vere suure glükoosisisalduse korral rohkem insuliini.
English: The maximum dose is 5 mg of linagliptin and 2,000 mg of metformin per day.
Estonian: Maksimaalne annus on 5 mg linagliptiini ja 2000 mg metformiini ööpäevas.
English: Why has Jentadueto been approved?
Estonian: Miks Jentadueto heaks kiideti?
English: If Jentadueto is taken with a sulphonylurea or insulin, the dose of these medicines may need to be lowered, to avoid hypoglycaemia (low blood sugar levels).
Estonian: Kui Jentaduetot võetakse koos sulfonüüluurearavimi või insuliiniga, võib olla vaja vähendada nende ravimite annuseid, et ennetada hüpoglükeemiat (vere liiga väike glükoosisisaldus).
English: For the full list of all side effects reported with Jentadueto, see the package leaflet.
Estonian: Jentadueto kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: What is the risk associated with Jentadueto?
Estonian: Mis riskid Jentaduetoga kaasnevad?
English: Linagliptin is a dipeptidyl-peptidase-4 (DPP 4) inhibitor.
Estonian: Linagliptiin on ensüümi dipeptidüülpeptidaas-4 (DPP-4) inhibiitor, mis blokeerib inkretiinhormoonide lagunemist.
English: When linagliptin and metformin were given with a sulphonylurea or insulin, hypoglycaemia was the most frequent side effect (seen in more than 1 patient in 10).
Estonian: Kui linagliptiini ja metformiini võeti koos sulfonüüluurearavimi või insuliiniga, oli kõige sagedam kõrvalnäht hüpoglükeemia (esinenud enam kui 1 patsiendil 10st).
English: The CHMP concluded that the combination of linagliptin and metformin has been shown to be effective at lowering HbA1c levels, and that linagliptin 2.5 mg twice per day was as effective as 5 mg once per day, which is approved in the EU for use on its own and in combination with metformin and with metformin plus a sulphonylurea or insulin.
Estonian: Inimravimite komitee järeldas, et linagliptiini ja metformiini kombineeritud kasutamine on HbA1csisalduse vähendamisel efektiivne ning et linagliptiin annuses 2,5 mg kaks korda ööpäevas on sama efektiivne kui 5 mg üks kord ööpäevas, mis on Euroopa Liidus heakskiidetud annus linagliptiini kasutamisel üksikravimina või koos metformiiniga või koos metformiini ja sulfonüüluurearavimi või insuliiniga.
English: Metformin was given at either 500 mg or 1,000 mg twice per day, for both the combination and the single treatment.
Estonian: Metformiini võeti kas 500 mg või 1000 mg kaks korda ööpäevas nii kombineeritud ravis kui ka üksikravimina.
English: Another study carried out in 1040 patients with type 2 diabetes compared patients taking 5 mg linagliptin and insulin given with metformin, with patients taking placebo given with insulin and metformin.
Estonian: Ühes uuringus (1040 II tüüpi diabeediga patsienti) võrreldi patsiente, kes võtsid 5 mg linagliptiini ja insuliini koos metformiiniga, patsientidega, kes võtsid platseebot koos insuliini ja meformiiniga.
English: The most frequent side effect with the combination of linagliptin plus metformin was diarrhoea (seen in around 2% of patients, with a similar rate seen in patients taking metformin plus placebo).
Estonian: Kõige sagedam kõrvalnäht linagliptiini ja metformiini kombineeritud kasutamisel oli kõhulahtisus (esinenud ligikaudu 2%-l patsientidest; sarnane sagedus esines ka metformiini ja platseebot võtnud patsientidel).
English: The studies with linagliptin showed that it was more effective than placebo at reducing HbA1c levels.
Estonian: Linagliptiini uuringutes selgus, et linagliptiin on HbA1c-sisalduse vähendamisel efektiivsem kui platseebo.
English: Metformin works mainly by inhibiting glucose production and reducing its absorption in the gut.
Estonian: Metformiin põhiliselt inhibeerib glükoosi tekkimist ja vähendab selle imendumist sooles.
English: Jentadueto is used in adults with type 2 diabetes to improve the control of blood glucose (sugar) levels.
Estonian: Jentaduetot kasutatakse II tüüpi diabeediga täiskasvanute raviks, et parandada vere glükoosisisalduse reguleeritavust organismis.
English: The study looking at adding linagliptin 2.5 mg twice per day or 5 mg once per day to metformin showed a similar reduction in HbA1c levels compared with placebo (0.74 and 0.80 points more than placebo respectively).
Estonian: Uuringus, milles jälgiti linagliptiini lisamist metformiinile annustes 2,5 mg kaks korda ööpäevas või 5 mg üks kord ööpäevas, vähenes HbA1c-sisaldus platseeboga võrreldes sarnaselt (vastavalt 0,74 ja 0,80 punkti võrra rohkem kui platseebo).
English: How does Jentadueto work?
Estonian: Kuidas Jentadueto toimib?
English: What benefit has Jentadueto shown during the studies?
Estonian: Milles seisneb uuringute põhjal Jentadueto kasulikkus?
English: The active substances in Jentadueto, linagliptin and metformin hydrochloride, each working in a different way.
Estonian: Jentadueto toimeainetel linagliptiinil ja metformiinvesinikkloriidil on eri toimemehhanismid.
English: • in combination with a sulphonylurea or insulin (other types of diabetes medicines) in patients who are not satisfactorily controlled on this medicine and metformin.
Estonian: • koos sulfonüüluurearavimiga (samuti diabeediravim), kui sulfonüüluurearavim ja metformiin ei anna patsiendi diabeediravis rahuldavat tulemust.
English: Another study was carried out involving 791 patients with type 2 diabetes, where the combination of linagliptin plus metformin given twice per day was compared with giving metformin alone, linagliptin alone or placebo.
Estonian: Ühes uuringus (791 II tüüpi diabeediga patsienti) võrreldi kaks korda ööpäevas võetavat linagliptiini ja metformiini kombinatsiooni ainult metformiini, ainult linagliptiini või platseeboga.
English: How has Jentadueto been studied?
Estonian: Kuidas Jentaduenot uuriti?
English: The study looking at linagliptin in combination with metformin and insulin showed that this combination was more effective than the combination of insulin and metformin at reducing HbA1c levels (reduction of 0.77 percentage points was seen with linagliptin compared with a reduction of 0.10 percentage points with placebo).
Estonian: Uuringus, milles jälgiti linagliptiini kasutamist koos metformiini ja insuliiniga, selgus, et see kombinatsioon vähendas HbA1c-sisaldust insuliini ja metformiini kombinatsioonist efektiivsemalt (linagliptiini korral oli tulemus 0,77% võrra väiksem ja platseebo korral 0,10% võrra väiksem).
English: When given in combination, linagliptin with metformin gave a reduction of 0.56 points compared with a rise of 0.10 points; linagliptin with metformin plus a sulphonylurea gave a reduction of 0.72 points compared with 0.10 points.
Estonian: Kombineeritud ravis koos metformiiniga vähenes tulemus linagliptiini korral 0,56 punkti ja platseebo korral suurenes 0,10 punkti ning koos metformiini ja sulfonüüluurearavimiga kasutamisel vähenes tulemus linagliptiini korral 0,72 punkti ja platseebo korral suurenes 0,10 punkti.
English: When used on its own, linagliptin gave a reduction of 0.46 points compared with a rise of 0.22 points.
Estonian: Üksikravimina kasutamise uuringus vähenes tulemus linagliptiini korral 0,46 punkti ja platseebo korral suurenes 0,22 punkti.